PALATIN TECHNOLOGIES INC(PTNTD.US)

Company Encyclopedia

PALATIN TECHNOLOGIES INC

PTNTD.US

1.944 T

PTNTD.USMarket value -Rank by Market Cap -/-

Financial Score

24/01/2026 Update

BiotechnologyIndustry

Industry Ranking353/397

Industry medianC

Industry averageD

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreB
- ROE970.33%A
- Profit Margin-6665.14%E
- Gross Margin0.00%E
Growth ScoreE
- Revenue YoY-94.07%E
- Net Profit YoY25.48%B
- Total Assets YoY-67.31%E
- Net Assets YoY-504.52%E
Cash ScoreE
- Cash Flow Margin-1.50%D
- OCF YoY-94.07%E
Operating ScoreE
- Turnover0.05E
Debt ScoreE
- Gearing Ratio271.31%E

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

Palamina Corp. Grants 4 Million Stock Options to Management and Advisors

Palamina Corp. has granted 4,025,000 stock options to its management and advisors under its Stock Option Plan, exercisable at $0.16 per share. The options for officers, directors, and advisors will expire on January 21, 2031, while those for consultants will expire on January 21, 2029. This announcement is for informational purposes only and should not be considered financial or legal advice.

Reuters·01/21/2026 09:51

Reuters·01/21/2026 09:51

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 | PTN Stock News

Palatin Technologies, Inc. presented promising preclinical data on its melanocortin agonists PL9654 and PL9655 for treating diabetic retinopathy at the ARVO 2025 Annual Meeting. The findings indicate that these compounds can resolve inflammation, stabilize the blood-retinal barrier, and protect retinal cells, showing efficacy across various models and administration routes. The results support further development of these agents, which could transform treatment for diabetic retinopathy, a leading cause of vision loss. Palatin aims to develop innovative therapies targeting the melanocortin receptor system.

StockTitan·05/09/2025 19:30

StockTitan·05/09/2025 19:30

Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News

Palatin Technologies, Inc. has announced the closing of a reduced public offering, raising approximately $1.1 million through the sale of 7,324,119 shares of common stock and associated Series F, G, and H warrants. The offering was conducted with institutional and accredited investors at a price of $0.15 per share. Proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as the lead placement agent. The company is focused on developing first-in-class biopharmaceuticals targeting the melanocortin receptor system.

StockTitan·05/09/2025 10:19

StockTitan·05/09/2025 10:19

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News

Palatin Technologies presented promising Phase 3 data for PL9643, a potential first-in-class treatment for dry eye disease (DED), at the 2025 ARVO Annual Meeting. The study showed statistically significant symptom resolution across multiple endpoints, with 6 of 13 endpoints achieving significance. PL9643 demonstrated rapid onset of action and was well tolerated. The findings highlight PL9643's potential to address unmet needs in DED treatment, with further studies planned for 2025-2026. The DED market is projected to grow significantly, indicating a strong opportunity for PL9643.

StockTitan·05/09/2025 04:39

StockTitan·05/09/2025 04:39